The Zhitong Finance App learned that recently, China's pharmaceutical innovation field ushered in a landmark development — GPN01530, a globally innovative radionuclide conjugate drug (RDC) independently developed by Yuanda Pharmaceutical (00512.HK), was officially approved by the FDA to conduct phase I/II clinical research in the US to diagnose solid tumors.

The Zhitong Finance App learned that recently, China's pharmaceutical innovation field ushered in a landmark development — GPN01530, a globally innovative radionuclide conjugate drug (RDC) independently developed by Yuanda Pharmaceutical (00512.HK), was officially approved by the FDA to conduct phase I/II clinical research in the US to diagnose solid tumors.